Loading
A phase 1/2 trial of Cetrelimab in advanced solid tumours, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers is a phase 1/2 interventional study registered as NCT02908906 by Janssen Research & Development, LLC, with 234 participants enrolled, started 2016-11-21 and due to reach its primary completion in 2023-11-17. Interventions recorded: JNJ-63723283.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/